-DOCSTART- -X- O
The -X- _ O
recent -X- _ O
Zika -X- _ O
viral -X- _ O
( -X- _ O
ZIKV -X- _ O
) -X- _ O
epidemic -X- _ O
has -X- _ O
been -X- _ O
associated -X- _ O
with -X- _ O
severe -X- _ O
neurological -X- _ O
pathologies -X- _ O
such -X- _ O
as -X- _ O
neonatal -X- _ O
microcephaly -X- _ O
and -X- _ O
Guillain-Barre -X- _ O
syndrome -X- _ O
but -X- _ O
unfortunately -X- _ O
no -X- _ O
vaccine -X- _ O
or -X- _ O
medication -X- _ O
is -X- _ O
effectively -X- _ O
available -X- _ O
yet. -X- _ O
Zika -X- _ B-Patient
NS2B-NS3pro -X- _ I-Patient
is -X- _ O
essential -X- _ O
for -X- _ O
the -X- _ O
proteolysis -X- _ O
of -X- _ O
the -X- _ O
viral -X- _ O
polyprotein -X- _ O
and -X- _ O
thereby -X- _ O
viral -X- _ O
replication. -X- _ O
Thus -X- _ O
NS2B-NS3pro -X- _ B-Patient
represents -X- _ O
an -X- _ O
attractive -X- _ O
target -X- _ O
for -X- _ O
anti-Zika -X- _ O
drug -X- _ O
discovery -X- _ O
/ -X- _ O
design. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
characterized -X- _ O
the -X- _ O
solution -X- _ O
conformations -X- _ O
and -X- _ O
catalytic -X- _ O
parameters -X- _ O
of -X- _ O
both -X- _ O
linked -X- _ B-Patient
and -X- _ I-Patient
unlinked -X- _ I-Patient
Zika -X- _ I-Patient
NS2B-NS3pro -X- _ I-Patient
complexes -X- _ I-Patient
and -X- _ O
found -X- _ O
that -X- _ O
the -X- _ O
unlinked -X- _ B-Outcome
complex -X- _ I-Outcome
manifested -X- _ I-Outcome
well-dispersed -X- _ I-Outcome
NMR -X- _ I-Outcome
spectra. -X- _ I-Outcome
Subsequently -X- _ O
with -X- _ O
selective -X- _ O
isotope-labeling -X- _ O
using -X- _ O
NMR -X- _ O
spectroscopy -X- _ O
, -X- _ O
we -X- _ O
demonstrated -X- _ O
that -X- _ O
C-terminal -X- _ B-Outcome
residues -X- _ I-Outcome
( -X- _ I-Outcome
R73-K100 -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
NS2B -X- _ I-Outcome
is -X- _ I-Outcome
highly -X- _ I-Outcome
disordered -X- _ I-Outcome
without -X- _ I-Outcome
any -X- _ I-Outcome
stable -X- _ I-Outcome
tertiary -X- _ I-Outcome
and -X- _ I-Outcome
secondary -X- _ I-Outcome
structures -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
Zika -X- _ I-Outcome
NS2B-NS3pro -X- _ I-Outcome
complex -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
free -X- _ I-Outcome
state. -X- _ I-Outcome
Upon -X- _ I-Outcome
binding -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
well-characterized -X- _ I-Outcome
serine -X- _ I-Outcome
protease -X- _ I-Outcome
inhibitor -X- _ I-Outcome
, -X- _ I-Outcome
bovine -X- _ I-Outcome
pancreatic -X- _ I-Outcome
trypsin -X- _ I-Outcome
inhibitor -X- _ I-Outcome
( -X- _ I-Outcome
BPTI -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
only -X- _ I-Outcome
the -X- _ I-Outcome
extreme -X- _ I-Outcome
C-terminal -X- _ I-Outcome
residues -X- _ I-Outcome
( -X- _ I-Outcome
L86- -X- _ I-Outcome
K100 -X- _ I-Outcome
) -X- _ I-Outcome
remain -X- _ I-Outcome
disordered. -X- _ I-Outcome
Additionally -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
identified -X- _ O
five -X- _ B-Intervention
flavonoids -X- _ I-Intervention
and -X- _ I-Intervention
one -X- _ I-Intervention
natural -X- _ I-Intervention
phenol -X- _ I-Intervention
rich -X- _ I-Intervention
in -X- _ I-Intervention
edible -X- _ I-Intervention
plants -X- _ I-Intervention
including -X- _ I-Intervention
fruits -X- _ I-Intervention
and -X- _ I-Intervention
vegetables -X- _ I-Intervention
, -X- _ O
which -X- _ O
inhibit -X- _ B-Outcome
Zika -X- _ I-Outcome
NS2B-NS3pro -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
non- -X- _ I-Outcome
competitive -X- _ I-Outcome
mode -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
Ki -X- _ I-Outcome
ranging -X- _ I-Outcome
from -X- _ I-Outcome
770 -X- _ I-Outcome
nM -X- _ I-Outcome
for -X- _ I-Outcome
Myricetin -X- _ I-Outcome
to -X- _ I-Outcome
34.02 -X- _ I-Outcome
Î¼M -X- _ I-Outcome
for -X- _ I-Outcome
Apigenin. -X- _ I-Outcome
Molecular -X- _ O
docking -X- _ O
showed -X- _ O
that -X- _ O
they -X- _ B-Outcome
all -X- _ I-Outcome
bind -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
pocket -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
back -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
active -X- _ I-Outcome
site -X- _ I-Outcome
and -X- _ O
their -X- _ O
structure- -X- _ O
activity -X- _ O
relationship -X- _ O
was -X- _ O
elucidated. -X- _ O
Our -X- _ O
study -X- _ O
provides -X- _ O
valuable -X- _ O
insights -X- _ O
into -X- _ O
the -X- _ O
solution -X- _ O
conformation -X- _ O
of -X- _ O
Zika -X- _ B-Patient
NS2B-NS3pro -X- _ I-Patient
and -X- _ O
further -X- _ O
deciphers -X- _ O
its -X- _ O
susceptibility -X- _ O
towards -X- _ O
allosteric -X- _ O
inhibition -X- _ O
by -X- _ O
natural -X- _ O
products. -X- _ O
As -X- _ O
these -X- _ O
natural -X- _ O
product -X- _ O
inhibitors -X- _ O
fundamentally -X- _ O
differ -X- _ O
from -X- _ O
the -X- _ O
currently-known -X- _ O
active -X- _ O
site -X- _ O
inhibitors -X- _ O
in -X- _ O
terms -X- _ O
of -X- _ O
both -X- _ O
inhibitory -X- _ O
mode -X- _ O
and -X- _ O
chemical -X- _ O
scaffold -X- _ O
, -X- _ O
our -X- _ O
finding -X- _ O
might -X- _ O
open -X- _ O
a -X- _ O
new -X- _ O
avenue -X- _ O
for -X- _ O
development -X- _ O
of -X- _ O
better -X- _ O
allosteric -X- _ O
inhibitors -X- _ O
to -X- _ O
fight -X- _ O
ZIKV -X- _ O
infection -X- _ O
. -X- _ O

